The protocol uses an investigational research platform, called the ‘PicostimTM-DyNeuMo,’ which was developed in a strategic collaboration between Professor Denison and Bioinduction, Ltd. Designed to be a configurable research platform, the team is now preparing funded trials using the PicostimTM-DyNeuMo in post-stroke chronic pain, epilepsy, and disorders of consciousness. The PicostimTM and PicostimTM-DyNeuMo research platform are available for investigational use only and are not approved for use outside of clinical studies. The Picostim™ DBS system is the world’s first miniaturized skull-mountable DBS system currently in pivotal clinical study ‘SPARKS’, the impulse generator (IPG) being one third of the size of conventional DBS devices. This is a rechargeable DBS device, where the Picostim™ DBS system has been designed to enable a faster, single-stage, implantation procedure.
